# Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma

> **NCT04581382** · EARLY_PHASE1 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 18 (actual)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** Nivolumab
- **BIOLOGICAL:** Pembrolizumab
- **RADIATION:** Radiation Therapy
- **BIOLOGICAL:** Therapeutic Exchange Plasma
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Positron Emission Tomography
- **PROCEDURE:** Magnetic Resonance Imaging

## Key facts

- **NCT ID:** NCT04581382
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-14
- **Primary completion:** 2024-10-06
- **Final completion:** 2024-10-06
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2025-07-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04581382

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04581382, "Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04581382. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*